PRESS RELEASE

Matt Sundermann, PhD Joins Pittsburgh-Based Contract Research Organization, Clinical Research Strategies, LLC as Senior Clinical and Regulatory Affairs Scientist

Pittsburgh, PA – March 4, 2024. Clinical Research Strategies, LLC (“CRS”), a Pittsburgh-area-based, US-owned and operated contract research organization (CRO) and executive management consultancy for the life sciences industry is pleased to announce the addition of Matt Sundermann, PhD, Senior Clinical and Regulatory Affairs Scientist, to the firm.

Dr. Sundermann earned an undergraduate Biomedical Engineering degree from Vanderbilt University in 2011 and a PhD in Bioengineering from the University of Pittsburgh in 2017. Prior to joining CRS, Matt held a Senior Clinical Strategy Manager role at Smith and Nephew and a Clinical Research Scientist role at ZOLL Medical Corporation. Between 2012-2017, he was employed in the UPMC Artificial Heart Program as a Clinical and Flight Engineer.

Matt Sundermann, PhD

Photo by Jen Worley

Outside of work, Matt is active with the Explorers Club of Pittsburgh and volunteers as an instructor in the club’s backpacking, climbing, and mountaineering schools. Matt resides in the Lawrenceville neighborhood of Pittsburgh with his partner Kelly and labrador retriever named Summit.

“Matt has phenomenal experience in key areas such as EU MDR, critical care, cardiovascular, orthopedic, emergency medicine, and life support that is a niche area of focus for a number of our clients,” says Alethea Wieland, CRS President and Founder. CEO, David Link, MBA adds, “We are excited for Matt to join us at CRS with his senior management-level experience in clinical and regulatory affairs, both in the US and in the EU.”

About Clinical Research Strategies, LLC:

CRS is a specialty CRO and executive management consulting firm that fits-for-purpose veteran life sciences executives, attorneys, regulatory scientists and strategists, clinical operations, project management, quality assurance engineers, and sales and marketing teams to take on the biggest challenges for start-up, mid-sized, and large life sciences companies, many of whom are developing novel, first-in-class drugs, biologics, diagnostics and medical devices, or software as a medical device (SaMD). Service areas are clinical trials, Functional Service Provider (FSP) models, selection and management of CROs, regulatory compliance strategy and submissions, QMS, EU MDR and GDPR, rescue trials, TMF, risk mitigation and remediation, training high-performing teams, staffing solutions, and decentralized trials. 

Indications represented are precision medicine, immuno-oncology, central nervous system, infectious diseases, respiratory diseases, orthopedics, de novo devices, digital health and mobile apps, reproductive health, regenerative medicine, cardiology, major depressive disorder, opioid-sparing pain, cannabis, radiology, and critical care. CRS is a qualified service provider for federal grants.

CRS is an inclusive employer and does not discriminate in employment on the basis of race, color, religion, sex, gender identity, national origin, political affiliation, sexual orientation, marital status, disability, genetic information, age, education, membership in an employee organization, parental status, military service, vaccine status, or other non-merit factor. CRS does not tolerate censorship, surveillance, bullying, intimidation, retaliation, discrimination, or harassment of any kind.

# # #

Media Contact:
Ron MacDonald
Step2 Branding and Design
ronmac@step2branding.com
+1 724.814.4067

Alethea Wieland, President and Founder
Clinical Research Strategies, LLC
alethea@clinicalresearchstrategies.com
+1 724.272.1245

 

Download this press release as a PDF.

Share This